Strides Pharma Science Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/mt32kbmbqmnlimm84d60ywcr.pdf

Key Takeaways


US Business: The Margin-First Turnaround

Arun Kumar: "We will not be in any urgency to grow the US business at a pace that we won't be able to manage and retain our profit strategy."

Other Regulated Markets & Institutional Business: Temporary Dips


Stelis: Regulatory Progress, Strategic Review, and the Path to Breakeven

Arun Kumar: "No, it doesn't, because you can't be a CDMO and a product company at the same time. It is a conflict of interest."

Margins, Costs & the Balance Sheet


Portfolio Catalysts & Other Updates

Arun Kumar: "I can reassure the investors that there are no contingencies surrounding this payment..."

Guidance & Commitments

CommitmentSpecificsTimeline
US gross margin exit run rateExit FY23 at 60% GM run rateFY23 exit
US revenue exit run rate$240–250 million exit run rateFY23 exit
Other regulated markets recoveryReturn to $40 million quarterly run rateQ3 FY23 (current quarter)
EBITDA margin expansionExpand from 11% to 15–17%Within FY23
EBITDA margin target21–22% EBITDA marginFY24 (if discipline continues for 2–3 quarters)
OPEX reductionAt least Rs. 150 crores reduction over current levelsFlow-through visible next year
Net debt reductionRs. 1,000 crores reduction, most in H2FY23
Exit net debt to EBITDABelow 3x, based on Q4 EBITDA annualized (>Rs. 150 crores)FY23 exit
Stelis debt reductionRs. 500 crores infusion reduces debt to Rs. 600 croresBefore end of FY23
Stelis cash breakevenBiopharma business reaches cash breakeven~18 months
Stelis strategic updateConcrete update on strategic processMarch 2023
Arrotex consideration$94 million receiptDecember 31 (working to bring forward)
Kauliv national approvalsNational registrations across European countries5–6 months
AmbiVax resubmissionAdditional clinical work completed and resubmitted2–3 months
Institutional business recoveryNew contracts awarded and business resumesQ4 FY23

Key Metrics

MetricQ2 FY23
US business quarterly run rate$60 million, benefiting from seasonality, new launches, and Chestnut Ridge integration
US business gross margin57%, driven by cost reduction, improved product mix, and lower logistics costs
US business gross margin target (exit FY23)60%, historical run rate
US business full-year revenue guidance$250 million, exit run rate of $240–$250 million; absolute may be $10–$15 million less
US business H1 revenue$106 million
Other regulated markets revenue impact₹60–70 crore reduction, one-off due to shift from B2C to B2B model, especially in Germany
Other regulated markets historical quarterly run rate~$40 million, expected to return to this level as early as Q3
Institutional business H1 revenue$39 million, with 0 order book currently as new contracts not yet awarded
Consolidated gross margin57%, sustainable and expected to grow modestly
EBITDA margin11%, double-digit after 4–5 quarters; expansion to 15–17% expected within FY23
EBITDA margin target (previously indicated)21–22% by FY24
Interest cost₹46.6 crore, similar to last quarter on a net basis
Net debt increase~₹200 crore, of which ₹145 crore from exchange rate movement between 1 Apr and 30 Sep
Net debt (current)Over ₹2,000 crore, up from ₹1,350 crore in FY22; ₹700 crore of FY22 figure was equity investment in Stelis
OPEX reduction completed$25–30 million, with further $11 million reduction from US headcount actions expected
OPEX reduction target (annualized)At least ₹150 crore over current level, flow-through visible next year
Stelis additional capital infusion₹500 crore committed by promoters and TPG
Stelis debt reduction (group level)₹1,300–1,500 crore between Strides and Stelis
Stelis current debt₹1,100 crore, expected to reduce to ₹600 crore after infusion
Stelis breakeven timeline18 months
Arrotex consideration (first part)$94 million, due by 31 Dec contractual date
Arrotex consideration (second part)$12 million, subject to certain conditions
PTH (Kauliv) global market opportunity$800 million, Europe ~$200 million; 20+ customers signed
New CDMO customers onboarded (Stelis)3 during the quarter
US portfolio approved products~260 approved; 65 Endo products launched; 20+ pending approval
Additional viable products in unlaunched/relaunched portfolio80–100 products expected to meet ~60% GM and 22–23% EBITDA criteria
Products with BE studies availableOver 300
Target new launches per year~20
US portfolio guided revenue range$400–500 million
Average revenue per small/niche product$3–5 million
Products exited that did not fit model$25–30 million of products removed
Guided debt reduction₹1,000 crore, most in H2
Exit net debt to EBITDA targetLess than 3x
Q4 EBITDA expectedMore than ₹150 crore